Thibaud Kössler, MD, PhD, of Geneva University Hospital, Geneva, Switzerland, discusses the rationale and trial design of PEMREC (NCT04109755), an ongoing Phase II study evaluating safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy (RT) in localized microsatellite stable rectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).